Top Page
Extrawell Pharmaceutical Holdings Limited
(0858)
Extrawell Pharmaceutical Holdings Limited (0858) vs. iShares MSCI Hong Kong ETF (EWH)
Extrawell Pharmaceutical Holdings Limited Business Overview & Revenue Model
Extrawell Pharmaceutical Holdings Limited Financial Statement Overview
| Breakdown | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 55.43M | 59.10M | 72.58M | 73.92M | 78.80M |
| Gross Profit | 21.87M | 28.78M | 31.14M | 37.56M | 42.57M |
| EBITDA | 255.11M | -129.52M | 155.20M | 157.84M | -97.48M |
| Net Income | 222.64M | -162.95M | 129.26M | 130.59M | -121.10M |
Balance Sheet | |||||
| Total Assets | 1.53B | 1.29B | 1.44B | 1.32B | 1.16B |
| Cash, Cash Equivalents and Short-Term Investments | 994.86M | 95.01M | 123.96M | 135.52M | 150.18M |
| Total Debt | 140.94M | 120.41M | 615.58M | 597.67M | 586.23M |
| Total Liabilities | 191.55M | 174.58M | 671.28M | 659.53M | 642.36M |
| Stockholders Equity | 1.33B | 1.11B | 769.36M | 653.29M | 518.15M |
Cash Flow | |||||
| Free Cash Flow | -7.44M | -4.89M | -3.40M | -11.23M | -953.00K |
| Operating Cash Flow | -4.37M | -3.69M | 3.21M | -1.60M | -232.00K |
| Investing Cash Flow | -9.38M | 2.04M | -12.50M | -9.63M | -681.00K |
| Financing Cash Flow | -1.58M | -6.50M | -2.29M | -1.80M | -1.69M |
Extrawell Pharmaceutical Holdings Limited Technical Analysis
Extrawell Pharmaceutical Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$204.00M | -0.15 | -30.35% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$845.51M | -2.84 | -48.86% | ― | -43.46% | -96.48% | |
48 Neutral | HK$159.80M | -38.07 | -8.95% | ― | 2.54% | 33.33% | |
47 Neutral | HK$45.75M | 4.26 | -3.06% | ― | -40.37% | -112.64% | |
46 Neutral | HK$167.36M | -0.14 | -41.48% | ― | 6.55% | -475.22% | |
41 Neutral | HK$173.85M | -2.22 | -36.23% | ― | -17.32% | 55.74% |
Extrawell Pharmaceutical Holdings Limited Corporate Events
Extrawell Pharmaceutical has agreed with bondholder Starcoin to extend the long stop date for completing the fourth set of amendments to its bond terms from 31 March 2026 to 30 June 2026. The change allows more time to satisfy precedent conditions and preserves the effectiveness of the amendment deed, reducing the risk that the revised bond arrangements lapse and potentially easing near-term financing uncertainty.
The company also announced a delay in sending a shareholder circular on the major transaction related to the bond amendments, pushing the expected despatch date from on or before 6 March 2026 to on or before 30 May 2026. This postponement, driven by the need to finalise information, slows the timetable for shareholder approval via a special general meeting and may briefly extend uncertainty for investors assessing the impact of the revised bond terms.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.08 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings has announced board and committee changes effective 20 January 2026, with long-serving independent non-executive director (INED) Fang Lin Hu resigning from the board and from his roles as chairman of the audit and remuneration committees and member of the nomination committee, citing advanced age and a desire to focus on family. He leaves without any disputes with the board. The company has appointed private equity veteran Yang Xiaorong as a new INED, bringing extensive experience in risk management, governance frameworks, compliance and institutional process design, as well as a background in government-affiliated organizations in Shanghai, which is expected to strengthen the Group’s corporate governance and oversight capabilities; she will receive an annual director’s fee of HK$70,000 and will be subject to shareholder re-election in line with the company’s bye-laws.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.10 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings Limited has announced the current composition of its board of directors, led by Chairman Dr. Xie Yi and Chief Executive Officer Dr. Guo Yi, alongside a team of executive and independent non-executive directors. The company also confirmed the membership of its three key board committees—Audit, Remuneration and Nomination—signalling a defined corporate governance structure with independent directors chairing the audit and remuneration functions, which is intended to support oversight, transparency and alignment with best-practice governance standards for stakeholders.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.10 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings Limited has announced that, effective 1 January 2026, the building name of its Hong Kong head office and principal place of business will change from Devon House to FWD Tower, with the full updated address now stated as Suites 2206–08, 22/F., FWD Tower, Taikoo Place, 979 King’s Road, Quarry Bay, Hong Kong. The change is purely nominal and does not involve any relocation, meaning the physical location and operational footprint of the company in Hong Kong remain unchanged, signalling no direct impact on ongoing business activities or stakeholder arrangements beyond administrative address updates.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical’s indirect subsidiary Changchun Extrawell has agreed to buy back a 10.06% equity stake from an existing substantial shareholder for RMB4.4 million, with the repurchased shares to be cancelled, raising the group’s interest in Changchun Extrawell from 80.46% to 89.46%. The transaction, classified as a discloseable and connected transaction at the subsidiary level under Hong Kong Listing Rules, has been approved by the board and endorsed as fair and reasonable by independent non-executive directors, is exempt from circular and independent shareholders’ approval requirements, and follows an earlier 2023 buy-back that previously lifted the group’s stake, underscoring Extrawell’s ongoing strategy to consolidate control of this key subsidiary while cautioning investors that completion remains subject to conditions precedent.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings has announced a leadership reshuffle effective 1 January 2026, separating the roles of chairman and chief executive officer as part of a broader push to enhance corporate governance and meet its evolving development needs. Long-serving chairman and CEO Dr. Xie Yi will step down from the chief executive role to concentrate on the company’s strategic direction while remaining as chairman and an executive director, with the board noting there is no disagreement behind his change in role. Executive director and genetics specialist Dr. Guo Yi, who has a background in biomedicine, healthcare and investment management and currently serves as a director of certain group subsidiaries, will take over as CEO without additional remuneration beyond his existing executive package and share options. The board underscored that the changes aim to improve segregation of duties and governance standards, signaling a more institutionalised management structure that may strengthen oversight and strategic execution for shareholders as the group pursues further growth in biomedicine and related fields.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings Limited, a Hong Kong-listed pharmaceutical company focused on the development, manufacture and sale of healthcare and drug products in Greater China, has announced the composition of its board and key governance committees effective 1 January 2026. The company confirmed a board led by Chairman Dr. Xie Yi and CEO Dr. Guo Yi, supported by executive and independent non-executive directors, and detailed the structure of its Audit, Remuneration and Nomination Committees, with independent non-executive director Mr. Fang Lin Hu chairing both the Audit and Remuneration Committees and Dr. Xie Yi chairing the Nomination Committee, underscoring the firm’s emphasis on corporate governance and oversight as it heads into the new year.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings Limited has granted a total of 76.5 million share options, representing about 3% of its issued share capital, to three executive directors under its 2022 share option scheme. The options, granted on 19 December 2025 at an exercise price of HK$0.0936 per share, will vest 12 months after the grant date and can be exercised for up to 10 years thereafter, with a nominal acceptance consideration and no performance targets attached, but subject to a clawback mechanism tied to misconduct and employment termination. The move underscores the company’s use of equity-based incentives to align management interests with shareholders, while limiting dilution through a relatively small percentage of new shares and confirming no financial assistance was provided to grantees for exercising the options.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.